Skip to content

Depreciation at other companies

Merck & Co. logo
Merck & Co.MRK
AbbVie logo
AbbVieABBV
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Gilead Sciences logo
Gilead SciencesGILD
Insmed logo
InsmedINSM

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's depreciation?
Summit Therapeutics (SMMT) reported depreciation of $44K in Q1 2026.
How has Summit Therapeutics's depreciation changed year-over-year?
Summit Therapeutics's depreciation increased by 76.0% year-over-year, from $25K to $44K.
What is the long-term trend for Summit Therapeutics's depreciation?
Over 4 years (2021 to 2025), Summit Therapeutics's depreciation has grown at a -18.4% compound annual growth rate (CAGR), from $330K to $146K.